List of references

Surendiran,A N. Balamurugan, Gunaseelan k, Shahid A, Reddy K S, and Adithan C (2010). Adverse drug reaction profile of cisplatin-based chemotherapy regimen in a tertiary care hospital in India: An evaluative study

Aleta J. Hong,1 Matthew J. Fisher,1 Christina H. Georgopoulos BS,2 and Charles L. Bennett, MD, PhD, MPP1 (2008). Identifying and reporting adverse drug events in oncology

Amartya De (2010).Monitoring of Suspected Adverse Drug Reactions in Oncology Unit of an Urban Multispeciality Teaching Hospital, *International Journal of Reserch in pharmaceutical & biomedical sciences.* vol.1 (2) **ISSN:2229-3701**,www.ijrpbsonline.com

Anju Prasad1, Pratyay Pratim Datta1, Jibak Bhattacharya, Chaitali Pattanayak, Ashok Singh Chauhan and Parbaty Panda(2013), Pattern of Adverse Drug Reactions Due to Cancer Chemotherapy in aTertiary Care Teaching Hospital in Eastern India, *JP* **01:2**

Apurva Agrawal1, Parul Chaturvedi2 (2012). AWARENESS, ATTITUDE AND PRACTICE OF PHARMACOVIGILANCE AMONG HEALTHCARE PROFESSIONALS AND STUDENTS IN A TERTIARY CARE TEACHING HOSPITAL IJCRR Vol 04 issue 17.

Chemotherapy in Tertiary Care Teaching Hospital in Bangladesh Dhaka Univ. J. Pharm. Sci**. 8(1) 11-16.**

COMMUNITY ONCOLOGY Vol 5/ No 5

Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN(2002). Cancer Incidence, Mortality and Prevalence Worldwide IARC **Cancer Base No. 5, version 2.0. IARC Press.**

Gor AP, Desai SV,(2008). Adverse drug reaction in the inpatients of medicine department of a rural tertiary care teaching hospital and influence of pharmacovigilance in reporting ADR. Indian J Pharmacol**,40(1)37-40.**

http://www.biomedcentral.com/**2050-6511/14/5**

Hussein G, Bleidt B, Belding B.(1999), Recognition, evaluation and reporting of adverse drug reactions**. Clinical Research & Reg, affairs, 16(3)91-107**.

Indian J Pharmacol **42(1) 40–43.**

J.H. Zong1, L. Eckert2, L. Zhang1, W.S. Dai1, A.T. Cohen3, G.H. Lyman4 (2012) oncology and public health © European Society for Medical Oncology. Annals of Oncology 23 (Supplement 9**): ix447–ix461.**

Kantarjian, HM; Jeha, S; Gandhi, V; Wess, M; Faderl, S (October 2007). "Clofarabine: past, present, and future.". Leukemia & lymphoma 48 (10) 1922–30. doi:10.1080/10428190701545644. **PMID 17852710.**

Kim JH, Kim HS, Choi JS, Lee KM, Shin YC, Ahn BM, et al.(2009). Bilateral subdural haemorrhage as a possible adverse event of gefitinib in a patient with non-small cell lung cancer. Lung Cancer**,64(1)121-3**.

Lal LS, Gerber DL, Lau J, Dana W.(2009). Retrospective evaluation of weekly paclitaxel hypersensitivity reactions reported utilizing an electronic medical record system at a tertiary cancer center. Support Care Cancer,**17(10)1311-5.**

Lateef M. Khan , Sameer . Al-Harthi , Omar . Saadah (2012) Adverse drug reactions in hospitalized pediatricpatients of Saudi Arabian University Hospitaland impact of pharmacovigilance in reporting ADR Saudi Pharmaceutical Journal (**2013) 21, 261–266**

Lau PM, Stewart K, Dooley M,(2004). The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you?. Support Care Cancer**. (9)626-33.**

Leki R, Saitoh E, Shibuya M.(2003). Acute lung injury as a possible adverse drug reaction related to gefitinib. Eur Respir J, **22(1)179-81**.

Lisa A. Ladewski, Steven M. Belknap, Jonathan R. Nebeker, Oliver Sartor, E. Allison Lyons, Timothy C. Kuzel, et al.(2003), Dissemination of information on potentially fatal adverse drug reactions for cancer drugs First results from the research on adverse drug events and reports project**. J Clin Oncol. 15,21(20)3859-66.**

Márcia Germana Alves de Araújo Lobo1, Sandra Maria Botelho Pinheiro2, José Gerley Díaz Castro3,Valéria Gomes Momenté4 and Maria-Cristina S Pranchevicius2 Lobo et al. (2013) Adverse drug reaction monitoring: support for pharmacovigilance at a tertiary care hospital in Northern Brazil, *BMC Pharmacology and Toxicology.*

Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. **2008 May 83(5)584-594.**

Parthasarathi G, Karin Nyfort-Hansen, Milap C Nahata. Adverse drug reactions. In: G Parthasarathi and Sten Olsson.(2007) A textbook of clinical pharmacy practice essentials concepts and skills. 1st ed. Chennai: **Orient Longman, 84-102.**

Patrick Medina, Chris Fausel.(2008). Cancer treatment and chemotherapy. In: Joseph T Dipiro, editor. **Pharmacotherapy a pathophysiologic approach. 7th ed. New York: McGraw-Hill companies P2085-119.**

Ravi S P, Subish P, Mishra P, Dubey A.K.(2006) Teaching pharmacovigilance to medical students and doctors. *Indian J Pharmacol***, 38(5)316-9.**

Ronald H.B. Meyboom, Antoine C.G.Egberts, Frank W.J. Gribnau, and Yechiel A. Hekster,

Sher T, Grace K, Adjei AA,(2008) Small cell lung cancer. Mayo Clin Proc. **83(3)355-367.**

Singh R, Sagar TG, Ramanan SG.(2004). 5-Fluorouracil cardio toxicity-revisited. Indian J Med Paediatr Oncol, **25(4)35-8.**

Sneegdha Poddar1, Razia Sultana1, Rebeka Sultana, Maruf Mohammad Akbor, Abul Kalam Azad and Abul Hasnat (2009). Pattern of Adverse Drug Reactions Due to Cancer

Subish PALAIAN, Mohamed I. M. IBRAHIM, Pranaya MISHRA.(2010) Pattern and quality of scientific communications on drug safety produced by a regional pharmacovigilance center in Nepal*, Nepal. Pharmacy Practice.***8(3)179-186**

V. Girre , H. Arkoub , M.T.E. Puts , C. Vantelon ,F. Blanchard , J.P. Droz , L. Mignot ,(2011) Potential drug interactions in elderly cancer patients Critical Reviews in Oncology/Hematology **78 (2011) 220–226**

Wang Z, Xu B, Lin D, Tan W, Leaw S, Hong X, et al.(2008), XRCC1 polymorphisms and severe toxicity in lung cancer patients treated with cisplatin-based chemotherapy in Chinese population. Lung Cancer **,62(1)99-104**

WHO Drug Information, World Health Organization, Geneva. 1997,11(1)1-52. Available at: http://apps.who.int/medicinedocs/documents/s14162e/s14162e.pdf (Accessed on 26.11.2009).

(1999), Pharmacovigilance in prospective. Drug safety.Adis international limited, issue no,0114-5916/0012-0429 S 0950/0